Omega RecruitingEndocrinologist / Outpatient / M-F / Partnership Omega RecruitingEndocrinologist / Outpatient / M-F / PartnershipOakland, CAImmediate need for a BE/BC Endocrinologist to join a growing Endo group. Partnership is possible for the right candidate after 3 years of employment.
NOW Healthcare RecruitingEndocrinologist $550k/yr, partner track NOW Healthcare RecruitingEndocrinologist $550k/yr, partner trackSan Francisco, CA$450,000–$550,000 / yearBase Salary: $275,000 - $300,000 / year base salary (with experience) $350-400k yr after retention bonus and supervising bonus in first few years. Conveniently located just 45 minutes from Portland, Oregon surrounded by natural beauty and outdoor activities.
The Permanente Medical Group, Inc. - N.CaliforniaOB/GYN: Reproductive Endocrinologist Opportunity in San Francisco, CA | TPMG The Permanente Medical Group, Inc. - N.CaliforniaOB/GYN: Reproductive Endocrinologist Opportunity in San Francisco, CA | TPMGSan Francisco, CA$582,000–$600,000 / yearThe Permanente Medical Group, Inc., Northern California, (TPMG) is one of the largest medical groups in the nation with over 10,000 physicians, 21 medical centers, numerous clinics throughout Northern and Central California and an 80-year tradition of providing quality medical care. For information about other General OB/GYN & subspecialty opportunities, visit TPMG Physician Careers: https://northerncalifornia.permanente.org.
Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare DiseaseSan Francisco, CARemote$160,000–$180,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.